The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 01, 2020

Filed:

Aug. 29, 2017
Applicants:

Novartis Ag, Basel, CH;

The Trustees of the University of Pennsylvania, Philadelphia, PA (US);

Inventors:

Hilmar Erhard Ebersbach, Basel, CH;

Thomas Huber, Basel, CH;

Julia Jascur, Basel, CH;

Celeste Richardson, Cambridge, MA (US);

Reshma Singh, Cambridge, MA (US);

Huijuan Song, Shanghai, CN;

Qilong Wu, Shanghai, CN;

Jiquan Zhang, Shanghai, CN;

Assignees:

Novartis AG, Basel, CH;

The Trustees of the University of Pennsylvania, Philadelphia, PA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); C07K 14/725 (2006.01); C07K 16/30 (2006.01); A61K 39/395 (2006.01); A61K 31/436 (2006.01); C07K 14/705 (2006.01); A61K 35/28 (2015.01); A61K 31/711 (2006.01); A61K 38/17 (2006.01); A61K 45/06 (2006.01); C07K 14/715 (2006.01); A61K 48/00 (2006.01); A61K 39/00 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2851 (2013.01); A61K 31/436 (2013.01); A61K 31/711 (2013.01); A61K 35/28 (2013.01); A61K 38/1774 (2013.01); A61K 38/1793 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61K 48/00 (2013.01); C07K 14/7051 (2013.01); C07K 14/7056 (2013.01); C07K 14/70517 (2013.01); C07K 14/70578 (2013.01); C07K 14/7151 (2013.01); C07K 16/2803 (2013.01); C07K 16/30 (2013.01); C07K 16/3061 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); A61K 2039/5156 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/53 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2319/00 (2013.01); C07K 2319/03 (2013.01); C07K 2319/33 (2013.01); C07K 2319/70 (2013.01);
Abstract

The invention provides compositions and methods for treating diseases associated with expression of CD33. The invention also relates to chimeric antigen receptor (CAR) specific to CD33, vectors encoding the same, and recombinant T cells comprising the CD33 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD33 binding domain.


Find Patent Forward Citations

Loading…